Industry Policy Committee Clinical Trial Initiatives
As of September 1, 2024
| Company name | Activities being undertaken in relation to intractable and rare diseases |
|---|---|
| Kyowa Kirin Co. | Creation of clinical evidence that contributes to the consideration of treatment requests
We are conducting research on the current status of routine medical care to examine the relationship between various patient backgrounds (age/sex/comorbidities/history of treatment, etc.) and outcomes (laboratory values/clinical symptoms [objective evaluation by healthcare professionals]/interview/PRO [subjective evaluation by patients/caregivers]) and identify groups with a large burden of disease requiring further improvement in treatment. We are conducting research to identify groups with a high burden of disease that require further improvement in treatment.
We are conducting studies to collect information on important treatment issues (complications, etc.) that do not occur frequently in rare diseases with low incidence rates and to clarify the association (improvement/unchanged, etc.) with current treatment through integrated clinical studies conducted in various countries. |